AstraZeneca’s Head of US Oncology Mohit Manrao’s statement about FDA approval of NIAGARA regimen
“This post is intended for a US audience:
Working to extend survival for patients facing tough-to-treat cancers has been the driving force behind our push for new immunotherapy options.
The FDA approved AstraZeneca’s NIAGARA regimen in muscle-invasive bladder cancer (MIBC) – confirming that our medicine has the potential to transform outcomes for this patient population.
Chemotherapy plus surgery have long been the standard of care for people with MIBC but nearly 50% face disease recurrence.
The NIAGARA trial data unlocked the possibility of longer-term survival with a 32% reduced risk of recurrence and 25% reduced risk of death.
Moving immuno-oncology treatment earlier and attacking tumors from multiple angles is a strategy that we believe will rewrite the future of cancer care. Pushing the boundaries of science, as our team does every day, means that we can deliver powerful results for the MIBC patients we serve.” – Mohit Manrao, SVP, Head of US Oncology at AstraZeneca, shared on LinkedIn.
Watch OncoDaily’s exclusive interview with Shub Goel, on OncoDaily TV and read about NIAGARA and HIMALAYA updates from ESMO24.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023